spironolactone has been researched along with Complications of Diabetes Mellitus in 25 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective of this study was to evaluate the antihypertensive effect of low dose spironolactone added to triple therapy for resistant hypertension in patients with type 2 diabetes measured by ambulatory monitoring." | 9.17 | Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. ( Gram, J; Henriksen, JE; Jacobsen, IA; Oxlund, CS; Schousboe, K; Tarnow, L, 2013) |
| " Studies comparing the effect of spironolactone to placebo in patients with hypertension and DM were included." | 9.12 | A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 7.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| "A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%)." | 7.72 | Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. ( Aaronson, KD; Koelling, TM; Tamirisa, KP, 2004) |
| "No reports have described mycotic pseudoaneurysm in the aortic arch in a diabetic patient associated with primary aldosteronism." | 5.36 | Successful treatment of a mycotic aortic pseudoaneurysm in a patient with type 2 diabetes mellitus while treating primary aldosteronism with spironolactone. ( Fukata, M; Furukawa, H; Ito, H; Ito, Y; Konishi, T; Matsuzawa, Y; Nishikawa, T; Okura, K; Saito, J; Yoshimura, K, 2010) |
| "The primary objective of this study was to evaluate the antihypertensive effect of low dose spironolactone added to triple therapy for resistant hypertension in patients with type 2 diabetes measured by ambulatory monitoring." | 5.17 | Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. ( Gram, J; Henriksen, JE; Jacobsen, IA; Oxlund, CS; Schousboe, K; Tarnow, L, 2013) |
| "A total of 6,496 patients from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) were categorized into 4 groups by plasma glucose concentration: ≤4." | 5.16 | Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. ( Böhm, M; Dobre, D; Kindermann, I; Lamiral, Z; Mahfoud, F; Pitt, B; Rossignol, P; Tala, S; Turgonyi, E; Ukena, C; Zannad, F, 2012) |
| " Studies comparing the effect of spironolactone to placebo in patients with hypertension and DM were included." | 5.12 | A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 3.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| "A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%)." | 3.72 | Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. ( Aaronson, KD; Koelling, TM; Tamirisa, KP, 2004) |
| "No reports have described mycotic pseudoaneurysm in the aortic arch in a diabetic patient associated with primary aldosteronism." | 1.36 | Successful treatment of a mycotic aortic pseudoaneurysm in a patient with type 2 diabetes mellitus while treating primary aldosteronism with spironolactone. ( Fukata, M; Furukawa, H; Ito, H; Ito, Y; Konishi, T; Matsuzawa, Y; Nishikawa, T; Okura, K; Saito, J; Yoshimura, K, 2010) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (32.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, M | 1 |
| Heizati, M | 1 |
| Wang, L | 1 |
| Nurula, M | 1 |
| Yang, Z | 1 |
| Wang, Z | 1 |
| Abudoyreyimu, R | 1 |
| Wu, Z | 1 |
| Li, N | 1 |
| Agarwal, R | 1 |
| Rossignol, P | 2 |
| Mayo, MR | 1 |
| Conrad, A | 1 |
| Arthur, S | 1 |
| Williams, B | 1 |
| White, WB | 1 |
| Ming, Y | 1 |
| Stefano, GB | 1 |
| Kream, RM | 1 |
| Zhuang, Q | 1 |
| Azizi, M | 1 |
| Monge, M | 1 |
| Lorthioir, A | 1 |
| Bobrie, G | 1 |
| Amar, L | 1 |
| Oxlund, CS | 1 |
| Henriksen, JE | 1 |
| Tarnow, L | 1 |
| Schousboe, K | 1 |
| Gram, J | 1 |
| Jacobsen, IA | 1 |
| Rodilla, E | 1 |
| Costa, JA | 1 |
| Pérez-Lahiguera, F | 1 |
| González, C | 1 |
| Pascual, JM | 1 |
| Goyal, BR | 1 |
| Solanki, N | 1 |
| Goyal, RK | 1 |
| Mehta, AA | 1 |
| Ito, Y | 1 |
| Yoshimura, K | 1 |
| Matsuzawa, Y | 1 |
| Saito, J | 1 |
| Ito, H | 1 |
| Furukawa, H | 1 |
| Okura, K | 1 |
| Fukata, M | 1 |
| Konishi, T | 1 |
| Nishikawa, T | 1 |
| Ukena, C | 1 |
| Dobre, D | 1 |
| Mahfoud, F | 1 |
| Kindermann, I | 1 |
| Lamiral, Z | 1 |
| Tala, S | 1 |
| Turgonyi, E | 1 |
| Pitt, B | 2 |
| Böhm, M | 1 |
| Zannad, F | 1 |
| Smith, ES | 1 |
| Trussell, S | 1 |
| Mencer, LJ | 1 |
| Trifonov, IR | 1 |
| Jarman, PR | 1 |
| Mather, HM | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Pandia, MP | 1 |
| Bithal, PK | 1 |
| Gupta, M | 1 |
| Tamirisa, KP | 1 |
| Aaronson, KD | 1 |
| Koelling, TM | 1 |
| O'Keefe, JH | 1 |
| Abuissa, H | 1 |
| Almirall, J | 1 |
| Lopez, T | 1 |
| Wedler, B | 1 |
| Wüstenberg, PW | 1 |
| Naumann, G | 1 |
| Vaz, AJ | 1 |
| Zweifler, AJ | 1 |
| Esler, M | 1 |
| Neuberg, R | 1 |
| Căruntu, M | 1 |
| Mihail, A | 1 |
| Silverberg, DS | 1 |
| Kjellstrand, CM | 1 |
| Mohme-Lundholm, E | 1 |
| Schwarzbach, W | 1 |
| Haas, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride[NCT02122731] | Phase 4 | 80 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for spironolactone and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
Topics: Blood Glucose; Blood Pressure; Diabetes Complications; Humans; Hypertension; Inflammation; Kidney; K | 2021 |
Prevention of heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Complications; Heart Failure; Heart Transplantati | 2002 |
4 trials available for spironolactone and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
Topics: Adult; Aged; Albumins; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitori | 2013 |
Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS.
Topics: Aged; Blood Glucose; Diabetes Complications; Double-Blind Method; Eplerenone; Female; Humans; Hyperg | 2012 |
[Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
Topics: Acute Disease; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Eple | 2003 |
Clinical use of high doses of furosemide (Lasix) in the treatment of resistant nephrotic edema.
Topics: Adult; Clinical Trials as Topic; Diabetes Complications; Diuretics; Edema; Female; Furosemide; Glome | 1968 |
19 other studies available for spironolactone and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes.
Topics: Diabetes Complications; Humans; Hypertension; Polymers; Renal Insufficiency, Chronic; Spironolactone | 2021 |
Anti-Diabetogenic Properties of Mineralocorticoid Receptor Antagonists: Implications for Enhanced Safety and Efficacy of Post-Transplantation Pharmacotherapies.
Topics: Calcineurin; Calcineurin Inhibitors; Cyclosporine; Diabetes Complications; Diabetes Mellitus; Everol | 2019 |
Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword.
Topics: Blood Pressure; Diabetes Complications; Female; Humans; Hypertension; Male; Spironolactone | 2013 |
[Spironolactone in patients with resistant hypertension].
Topics: Aged; Confidence Intervals; Diabetes Complications; Diuretics; Drug Resistance; Female; Follow-Up St | 2008 |
Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes.
Topics: Animals; Blood; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Carrier Protein | 2009 |
Successful treatment of a mycotic aortic pseudoaneurysm in a patient with type 2 diabetes mellitus while treating primary aldosteronism with spironolactone.
Topics: Aged; Aneurysm, False; Aneurysm, Infected; Aortic Aneurysm; Blood Vessel Prosthesis Implantation; Di | 2010 |
Diabetes may be independent risk factor for hyperkalaemia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Complications; | 2003 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Life-threatening hyperkalemia in the intraoperative period.
Topics: Brain Neoplasms; Decompression, Surgical; Diabetes Complications; Diuretics; Glioma; Humans; Hyperka | 2004 |
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Algorithms; Body Weight; Case-Control Studies; Creat | 2004 |
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Eplerenone; Female; Heart Failure; Humans; H | 2008 |
Spironolactone and ACE inhibition in chronic renal failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Complications; Drug Therapy, Combination; Humans; | 2002 |
[Treatment of hypertonus in diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus; Eth | 1975 |
Clinical use of spironolactone.
Topics: Diabetes Complications; Humans; Hyperkalemia; Kidney Diseases; Spironolactone | 1979 |
Factors influencing the choice of antihypertensive agents.
Topics: Age Factors; Aldosterone; Cerebrovascular Disorders; Clonidine; Depression; Diabetes Complications; | 1976 |
Immunosuppression and plasmocytoma of the cervix.
Topics: Adult; Azathioprine; Diabetes Complications; Female; Furosemide; Humans; Immunosuppression Therapy; | 1974 |
[New aspects of the use of spironolactone and its association with thiabutazide (per os and in injections) in the treatment of grave cardiac insufficiency].
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Benzothiadiazines; Diabetes Complications; D | 1974 |
[Metyrapone treatment of resistant edema].
Topics: Adult; Chlorothiazide; Diabetes Complications; Edema; Humans; Male; Metyrapone; Prednisolone; Spiron | 1966 |
[Saluretic therapy and insulin resistance in diabetes mellitus].
Topics: Aged; Diabetes Complications; Diabetes Mellitus; Diabetic Coma; Female; Furosemide; Humans; Hyponatr | 1966 |